GHRP-6 vs TB-500
Well Studied vs Well Studied
compatible No negative interactions; potential enhanced recovery.
Molecular Data
GHRP-6 TB-500
Weight 873 Da 4,963.44 Da
Half-life 15-60 minutes ~2 hours
Chain 6 amino acids 43 amino acids
Type Synthetic hexapeptide Thymosin fragment
Key Benefits
GHRP-6
01 Potent stimulation of natural growth hormone release
02 Significant increase in appetite (beneficial for bulking/weight gain)
03 Enhanced muscle growth through elevated GH and IGF-1
04 Improved fat metabolism and body composition
05 Cardioprotective effects observed in research
06 Enhanced recovery from exercise and injury
07 Cytoprotective and anti-inflammatory properties
08 Maintains natural GH pulsatile release
TB-500
01 Superior systemic tissue repair
02 Accelerated muscle, tendon, and ligament healing
03 Enhanced cell migration and angiogenesis
04 Comprehensive regenerative effects
05 Neuroprotective properties
Dosing Protocols
GHRP-6
100-300 mcg per injection / 2-3 times daily (morning, post-workout optional, before bed)
GH optimization 100 mcg 2-3x daily
Enhanced results 200-300 mcg 2-3x daily
With GHRH (synergy) 100 mcg each 2-3x daily
Appetite/bulking 100-200 mcg Before meals
TB-500
2-5mg per injection (higher doses for serious injuries) / 2-3x weekly (e.g., Monday, Wednesday, Friday)
General tissue repair 2-3mg 2x weekly
Serious injury recovery 4-5mg 3x weekly
Athletic enhancement 2-3mg 2x weekly
Chronic conditions 3-4mg 2-3x weekly
Maintenance 2mg 1-2x weekly
Post-surgical recovery 3-5mg 3x weekly
Side Effects
GHRP-6
Intense hunger/increased appetite (most notable side effect)
Water retention
Tingling or numbness in extremities
Tiredness or lethargy after injection
Mild headache
TB-500
Generally minimal side effects
Possible mild injection site reactions
Temporary fatigue in some users
Contraindications
Active cancer or history of cancer
Pregnancy or breastfeeding
Pituitary disorders
Diabetes (use with caution)
WADA prohibited for competitive athletes
Active cancer treatment (due to angiogenic effects)
Pregnancy or breastfeeding
Immunosuppressive medications (consult provider)
WADA prohibited for competitive athletes
Research Evidence
GHRP-6 TB-500
Status Well Studied Well Studied
References 3 studies 4 studies
Latest — March 2024
FDA Approved No No
This comparison is for educational and research purposes only. Consult a healthcare professional before use.